BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9808130)

  • 1. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study.
    Zaino RJ; Kurman RJ; Brunetto VL; Morrow CP; Bentley RC; Cappellari JO; Bitterman P
    Am J Surg Pathol; 1998 Nov; 22(11):1379-85. PubMed ID: 9808130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
    Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
    Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytologic features of villoglandular adenocarcinoma of the uterine cervix: comparison with typical endocervical adenocarcinoma with a villoglandular component and papillary serous carcinoma.
    Chang WC; Matisic JP; Zhou C; Thomson T; Clement PB; Hayes MM
    Cancer; 1999 Feb; 87(1):5-11. PubMed ID: 10096353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytomorphology of papillary serous carcinoma of the endometrium in cervical smears.
    Wright CA; Leiman G; Burgess SM
    Cancer; 1999 Feb; 87(1):12-8. PubMed ID: 10096354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A suggested modification to FIGO stage I endometrial cancer.
    Aristizabal P; Graesslin O; Barranger E; Clavel-Chapelon F; Haddad B; Luton D; Darai E; Rouzier R; Koskas M
    Gynecol Oncol; 2014 May; 133(2):192-6. PubMed ID: 24631453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
    Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson Jackson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
    Gynecol Oncol; 2023 Oct; 177():38-45. PubMed ID: 37634258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus.
    Ambros RA; Ballouk F; Malfetano JH; Ross JS
    Am J Surg Pathol; 1994 Jun; 18(6):569-75. PubMed ID: 8179072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium.
    Galic V; Schiavone MB; Herzog TJ; Holcomb K; Lewin SN; Lu YS; Neugut AI; Hershman DL; Wright JD
    Cancer Invest; 2013 Aug; 31(7):500-4. PubMed ID: 23915075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
    Bartosch C; Manuel Lopes J; Oliva E
    Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Villoglandular adenocarcinoma of the endometrium.
    Ambros RA; Malfetano JH
    Am J Surg Pathol; 2000 Jan; 24(1):155-6. PubMed ID: 10632501
    [No Abstract]   [Full Text] [Related]  

  • 15. Endometrioid endometrial adenocarcinoma with psammoma bodies.
    Parkash V; Carcangiu ML
    Am J Surg Pathol; 1997 Apr; 21(4):399-406. PubMed ID: 9130986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
    Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J
    Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
    McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
    Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation.
    Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
    Am J Clin Pathol; 1999 Mar; 111(3):336-42. PubMed ID: 10078108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.